(ASND) Ascendis Pharma AS - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 13.845m USD | Total Return: 21.5% in 12m
Avg Turnover: 116M
Qual. Beats: 0
Rev. Trend: 95.9%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -0.1 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -3.17 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company specializing in the development of long-acting prodrug therapies. The firm utilizes its proprietary TransCon (Transient Conjugation) technology platform to create treatments that release unmodified parent drugs at predictable rates, aiming to improve efficacy and patient compliance compared to conventional formulations.
The companys commercial portfolio includes SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adult chronic hypoparathyroidism. In the biotechnology sector, companies often utilize platform technologies like TransCon to develop multiple candidates across diverse therapeutic areas, including endocrinology and oncology, to mitigate clinical development risks. The high capital intensity of the rare disease market typically requires significant investment in research and development before achieving commercial profitability.
Investors can further examine the companys valuation metrics and clinical pipeline progress on ValueRay. Ascendis Pharma continues to advance its clinical pipeline with a focus on expanding its endocrinology presence and establishing a footprint in the oncology space.
- YORVIPATH commercial launch and market penetration drive long-term revenue growth expectations
- SKYTROFA market share expansion against established pediatric growth hormone competitors
- Clinical trial data readouts for TransCon pipeline candidates impact valuation
- Regulatory approval timelines for expanded indications determine future cash flow projections
- High research and development expenditures necessitate continued capital access and liquidity
| Net Income: 506.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 22.90 > 1.0 |
| NWC/Revenue: -0.51% < 20% (prev 9.76%; Δ -10.27% < -1%) |
| CFO/TA 0.03 > 3% & CFO 57.6m > Net Income 506.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.5m) vs 12m ago 7.50% < -2% |
| Gross Margin: 88.17% > 18% (prev 85.30%; Δ 2.87% > 0.5%) |
| Asset Turnover: 56.57% > 50% (prev 34.74%; Δ 21.84% > 0%) |
| Interest Coverage Ratio: -0.13 > 6 (EBIT TTM -24.3m / Interest Expense TTM 182.5m) |
| A: -0.00 (Total Current Assets 1.12b - Total Current Liabilities 1.13b) / Total Assets 2.01b |
| B: -1.04 (Retained Earnings -2.09b / Total Assets 2.01b) |
| C: -0.02 (EBIT TTM -24.3m / Avg Total Assets 1.53b) |
| D: 0.32 (Book Value of Equity 488.5m / Total Liabilities 1.52b) |
| Altman-Z'' = -3.17 = D |
| DSRI: 1.25 (Receivables 196.8m/66.7m, Revenue 867.5m/368.7m) |
| GMI: 0.97 (GM 85.30% / 88.17%) |
| AQI: 8.31 (AQ_t 0.37 / AQ_t-1 0.04) |
| SGI: 2.35 (Revenue 867.5m / 368.7m) |
| TATA: 0.22 (NI 506.6m - CFO 57.6m) / TA 2.01b) |
| Beneish M = 2.48 (Cap -4..+1) = D |
As of June 08, 2026, the stock is trading at USD 210.45 with a total of 553,651 shares traded.
Over the past week, the price has changed by -6.10%,
over one month by -14.50%,
over three months by -12.28% and
over the past year by +21.54%.
Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 298.4 | 41.8% |
Market Cap EUR = 12.0b (13.8b USD * 0.8661 USD.EUR)
P/E Trailing = 25.467
P/E Forward = 13.3156
P/S = 17.0209
P/B = 25.6213
Revenue TTM = 867.5m EUR
EBIT TTM = -24.3m EUR
EBITDA TTM = -6.94m EUR
Long Term Debt = 386.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 511.1m EUR (from shortTermDebt, last quarter)
Debt = 996.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 98.8m
Net Debt = 423.0m EUR (calculated: Debt 996.4m - CCE 573.4m)
Enterprise Value = 12.4b EUR (12.0b + Debt 996.4m - CCE 573.4m)
Interest Coverage Ratio = -0.13 (Ebit TTM -24.3m / Interest Expense TTM 182.5m)
EV/FCF = 294.8x (Enterprise Value 12.4b / FCF TTM 42.1m)
FCF Yield = 0.34% (FCF TTM 42.1m / Enterprise Value 12.4b)
FCF Margin = 4.85% (FCF TTM 42.1m / Revenue TTM 867.5m)
Net Margin = 58.40% (Net Income TTM 506.6m / Revenue TTM 867.5m)
Gross Margin = 88.17% ((Revenue TTM 867.5m - Cost of Revenue TTM 102.6m) / Revenue TTM)
Gross Margin QoQ = 91.37% (prev 88.91%)
Tobins Q-Ratio = 6.19 (Enterprise Value 12.4b / Total Assets 2.01b)
Interest Expense / Debt = 18.32% (Interest Expense 182.5m / Debt 996.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -19.2m (EBIT -24.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.00 (Total Current Assets 1.12b / Total Current Liabilities 1.13b)
Debt / Equity = 2.04 (Debt 996.4m / totalStockholderEquity, last quarter 488.5m)
Debt / EBITDA = -60.92 (negative EBITDA) (Net Debt 423.0m / EBITDA -6.94m)
Debt / FCF = 10.05 (Net Debt 423.0m / FCF TTM 42.1m)
Total Stockholder Equity = -8.98m (last 4 quarters mean from totalStockholderEquity)
RoA = 33.04% (Net Income 506.6m / Total Assets 2.01b)
RoE = -5.64k% (out of range, set to none) (Net Income TTM 506.6m / Total Stockholder Equity -8.98m)
RoCE = -6.45% (EBIT -24.3m / Capital Employed (Equity -8.98m + L.T.Debt 386.1m))
RoIC = -1.43% (negative operating profit) (NOPAT -19.2m / Invested Capital 1.35b)
WACC = 8.69% (E(12.0b)/V(13.0b) * Re(8.21%) + D(996.4m)/V(13.0b) * Rd(18.32%) * (1-Tc(0.21)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 5.98%
[DCF] Terminal Value 74.25% ; FCFF base≈42.1m ; Y1≈42.3m ; Y5≈44.8m
[DCF] Fair Price = 3.81 (EV 658.5m - Net Debt 423.0m = Equity 235.5m / Shares 61.8m; r=8.69% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.29 | # QB: 0
Revenue Correlation: 95.86 | Revenue CAGR: 86.50% | SUE: -0.41 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.70 | Chg30d=N/A | Revisions=N/A | Analysts=6
EPS next Quarter (2026-09-30): EPS=1.15 | Chg30d=N/A | Revisions=N/A | Analysts=6
EPS current Year (2026-12-31): EPS=11.44 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+217.5% | GrowthRev=+86.0%
EPS next Year (2027-12-31): EPS=9.42 | Chg30d=N/A | Revisions=N/A | GrowthEPS=-17.6% | GrowthRev=+45.0%